Physician profile
Rayson Yang
NPI 1841301637
$10,228.79
in general payments reported to CMS, 2019-2025
39 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $1,015 · 2021: $1,467 · 2022: $1,190 · 2023: $1,555 · 2024: $1,703 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,041.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,903.11 | 2019-2025 | Avvigo Guidance System, General - Vascular Access, Watchman Flx |
| Abbott Laboratories | $1,481.01 | 2019-2025 | Dragonfly Opstar, Diamondback Peripheral, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $1,455.83 | 2019-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $831.48 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $531.41 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $504.87 | 2020-2025 | Brilinta, Farxiga, Lynparza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $405.07 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $379.07 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $330.20 | 2019-2025 | |
| Amgen INC. | $285.96 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $274.92 | 2021-2025 | Verquvo |
| Cvrx, INC. | $212.78 | 2023-2025 | Barostim Neo System |
| Abiomed | $205.80 | 2024-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.41 | 2021-2025 | Jardiance |
| Atricure, INC. | $117.96 | 2023-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $117.51 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amarin Pharma, INC. | $98.88 | 2019-2022 | |
| Ekos Corporation | $93.15 | 2019 | |
| Bridgebio Pharma, INC. | $86.57 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $83.59 | 2022-2023 | |
| Esperion Therapeutics, INC. | $79.16 | 2020-2022 | |
| Shockwave Medical, INC | $68.97 | 2022 | |
| W. L. Gore & Associates, INC. | $65.74 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.20 | 2021-2025 | |
| Catheter Precision INC. | $40.89 | 2023 | |
| Tactile Systems Technology INC | $39.97 | 2020-2024 | Entre Plus, Flexitouch Plus |
| Kiniksa Pharmaceuticals, Ltd. | $39.56 | 2021 | |
| Gilead Sciences, INC. | $36.47 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $35.95 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $33.85 | 2024-2025 | Assure Wcd |
| Biotronik INC. | $32.59 | 2025 | Biomonitor |
| Lilly USA, LLC | $17.78 | 2025 | Zepbound |
| Potrero Medical, INC. | $17.12 | 2023 | |
| Ge Healthcare | $17.12 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $16.87 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.30 | 2024 | Amvuttra |
| Cashflow Solutions, LLC | $15.10 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2021 | |
| Bardy Diagnostics, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayson Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.